NASDAQ
36.02USD
-0.35 (-0.96%)
We have scored 11 news catalysts on Pharvaris N.V. (PHVS) over the past 12 months. The biggest single-day move next to one of them came Dec 4, 2025, when PHVS closed −5.7%: “Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals”. Coverage across the window leans positive (average ticker sentiment +0.69). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.5B
P/E
—
EPS
—
Beta
-2.32
52W range
20.65-43.25
Day range
35.50–36.88
Open
36.33
Prev close
36.37
Volume
653.7K
Avg volume
603.2K
Dividend
0.00
IPO
2021-02-04
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Pharvaris N.V. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PHVS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
